Findings

What do systematic reviews say?

90 questions · 91 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 4.4%GRADE not reported 59 · 64.8%Very low 25 · 27.5%Low 3 · 3.3%Moderate 0 · 0%High 0 · 0%

Zuclopenthixol dihydrochloride vs trifluoperazine

Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs trifluoperazine

Adverse effects: Clinically important general adverse effect (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs trifluoperazine

Death: Suicide and natural causes (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs trifluoperazine

Length of hospital stay · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs trifluoperazine

Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs trifluoperazine

Leaving the study early · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Very low

Zuclopenthixol dihydrochloride vs placebo

General functioning: Average endpoint general functioning score (clinically improved) (no data) · patients with schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs trifluoperazine

General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Adverse effects: Clinically important general adverse effect (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Death: Suicide and natural causes (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Length of hospital stay · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Mental state: Average endpoint general mental state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

Leaving the study early · schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 1.95 [0.36, 10.58]
1 study · 46 participants
Very low

Zuclopenthixol dihydrochloride vs zuclopenthixol depot

General functioning: Average endpoint general functioning score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

Global state: Average endpoint global state score (clinically improved) (no data) · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Very low

Zuclopenthixol dihydrochloride vs chlorpromazine

Adverse effects: Clinically important general adverse effect (EPSEs) · schizophrenia

It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect (EPSEs) compared with chlorpromazine (very low certainty).

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
RR 0.94 [0.61, 1.45]
3 studies · 199 participants
Very low

Zuclopenthixol dihydrochloride vs placebo

Clinically significant response on global state · patients with schizophrenia

It is very uncertain whether ZUCLOPENTHIXOL DIHYDROCHLORIDE changes clinically significant response on global state ‐ as defined by each… compared with PLACEBO (very low certainty).

1 finding from 1 review

Zuclopenthixol versus placebo for schizophrenia 2015 · Cochrane Headline outcomes only
RR 2.57 [1.06, 6.2]
1 study · 29 participants
Very low

Zuclopenthixol dihydrochloride vs placebo

Relapse · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Zuclopenthixol versus placebo for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zuclopenthixol dihydrochloride vs placebo

Clinically significant response on psychotic symptoms ‐ as defined by each of the studies. · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Zuclopenthixol versus placebo for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found